| P50 | author | Julia Romanova | Q59680520 |
| P2093 | author name string | Andrej Egorov | |
| | Boris Ferko | |
| | Hermann Katinger | |
| | Christian Kittel | |
| | Sabine Sereinig | |
| P2860 | cites work | An improved reverse genetics system for influenza A virus generation and its implications for vaccine production | Q24537680 |
| | Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. | Q28609759 |
| | Influenza A subtype cross-protection after immunization of outbred mice with a purified chimeric NS1/HA2 influenza virus protein | Q45784047 |
| | Increased anti-influenza A virus cytotoxic T cell activity following vaccination of the chronically ill elderly with live attenuated or inactivated influenza virus vaccine | Q45784978 |
| | Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection | Q45831152 |
| | Recombinant interleukin 2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines | Q45842212 |
| | Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract | Q47953307 |
| | A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. | Q50686159 |
| | Coadministration of interleukin 2 plasmid DNA with combined DNA vaccines significantly enhances the protective efficacy against Mycobacterium tuberculosis. | Q51339029 |
| | Attenuation and immunogenicity in mice of temperature-sensitive influenza viruses expressing truncated NS1 proteins. | Q51349178 |
| | Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. | Q51525879 |
| | Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. | Q51729193 |
| | Defective generation but normal maintenance of memory T cells in old mice. | Q52011697 |
| | The defects in effector generation associated with aging can be reversed by addition of IL-2 but not other related gamma(c)-receptor binding cytokines. | Q52028930 |
| | The immune response of aged mice to influenza: diminished T-cell proliferation, interleukin 2 production and cytotoxicity. | Q52214293 |
| | Interleukin 2 increases protection against experimental rabies. | Q53414964 |
| | Cytotoxic T-cell immunity to influenza. | Q55062679 |
| | Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity | Q64131545 |
| | In vivo T cell activation, in vitro defective IL-2 secretion, and response to influenza vaccination in elderly women | Q67728782 |
| | Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME-VAC) in young adults | Q73038010 |
| | Mucosal vaccination and immune responses in the elderly | Q73480287 |
| | Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents | Q73520468 |
| | Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens | Q77302768 |
| | Role of humoral and cell-mediated immunity in protection from influenza disease after immunization of healthy elderly | Q77436729 |
| | Oral administration with papillomavirus pseudovirus encoding IL-2 fully restores mucosal and systemic immune responses to vaccinations in aged mice | Q80418726 |
| | Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18 | Q81158144 |
| | Cellular antiviral responses against influenza A virus are countered at the posttranscriptional level by the viral NS1A protein via its binding to a cellular protein required for the 3' end processing of cellular pre-mRNAS | Q28609773 |
| | A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice | Q28609778 |
| | Influenza A Virus Lacking the NS1 Gene Replicates in Interferon-Deficient Systems | Q29039793 |
| | Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. | Q30328341 |
| | Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. | Q30350391 |
| | The development of live attenuated cold-adapted influenza virus vaccine for humans | Q33782441 |
| | Attenuation of equine influenza viruses through truncations of the NS1 protein | Q33843410 |
| | Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice | Q33844931 |
| | Rescue of influenza A virus from recombinant DNA. | Q33846053 |
| | Immunity to influenza in the elderly | Q33846375 |
| | Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine | Q33867863 |
| | Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach | Q33895154 |
| | Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. | Q33965589 |
| | Type I IFN is a powerful mucosal adjuvant for a selective intranasal vaccination against influenza virus in mice and affects antigen capture at mucosal level. | Q33986226 |
| | Functional replacement of the carboxy-terminal two-thirds of the influenza A virus NS1 protein with short heterologous dimerization domains. | Q34351597 |
| | Defense against influenza A virus infection: essential role of the chemokine system | Q34532119 |
| | Influenza vaccines: present and future | Q34717840 |
| | Intracellular warfare between human influenza viruses and human cells: the roles of the viral NS1 protein | Q35131981 |
| | Prospects for Human Mucosal Vaccines | Q35210784 |
| | Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines | Q35629114 |
| | Molecular adjuvants for mucosal immunity | Q35826381 |
| | Gene-based vaccines and immunotherapeutics | Q35873176 |
| | The influenza virus NS1 protein is a poly(A)-binding protein that inhibits nuclear export of mRNAs containing poly(A) | Q36632150 |
| | Immunoglobulin A mediation of murine nasal anti-influenza virus immunity | Q36684724 |
| | Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus | Q37207762 |
| | Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. | Q37596474 |
| | The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines | Q39303124 |
| | Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2. | Q40361792 |
| | Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment | Q40391888 |
| | Live cold-adapted influenza A vaccine produced in Vero cell line | Q40551691 |
| | Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries? | Q40888801 |
| | In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific | Q42937027 |
| | Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine | Q43459234 |
| | Age-related impairment of human T lymphocytes' activation: specific differences between CD4(+) and CD8(+) subsets | Q43823312 |
| | Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract | Q45153042 |
| | Antibody responses and protection against influenza virus infection in different congenic strains of mice immunized intranasally with adjuvant-combined A/Beijing/262/95 (H1N1) virus hemagglutinin or neuraminidase. | Q45730050 |
| | Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine | Q45743764 |
| | Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine | Q45744752 |
| | Induction of mucosal antibodies by live attenuated and inactivated influenza virus vaccines in the chronically ill elderly | Q45771986 |
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | attenuated vaccine | Q1810913 |
| P304 | page(s) | 11621-11627 | |
| P577 | publication date | 2006-09-13 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts | |
| P478 | volume | 80 | |